Amarin: Is a Buyout Really Off the Table?

Amarin (NASDAQ: AMRN) drew the ire of its shareholders last week by rolling out a breathtaking $460 million capital raise. The drugmaker's shares, in fact, fell by a noteworthy 17.4% last week in large part because of the sheer size of this public offering.